Drug Makers Hike Prices, Lobby Hard As Reform Efforts Progress

Main Category: Pharma Industry / Biotech Industry
Also Included In: Public Health;  Regulatory Affairs / Drug Approvals
Article Date: 17 Nov 2009 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect." The increases "will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year."

"Drug makers say they have valid business reasons for the price increases. Critics say the industry is trying to establish a higher price base before Congress passes legislation that tries to curb drug spending in coming years" (Wilson, 11/15).

In a separate story, the Times reports that Genentech, a subsidiary the Swiss drug maker Roche, succeeded in getting "estimates that 42 House members picked up some of its talking points - 22 Republicans and 20 Democrats, an unusual bipartisan coup for lobbyists." The remarks appeared in the Congressional Record.

"Statements by more than a dozen lawmakers were ghostwritten, in whole or in part, by Washington lobbyists working for Genentech, one of the world's largest biotechnology companies. … E-mail messages obtained by The New York Times show that the lobbyists drafted one statement for Democrats and another for Republicans." The statements emphasized that a provision regulating the FDA's power to approve generic biotechnology drugs that came out favorably for companies like Genentech would help preserve American jobs.

"The statements were not intended to change the bill, which was not open for much amendment during the debate. They were meant to show bipartisan support for certain provisions, even though the vote on passage generally followed party lines" (Pear, 11/14).

This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org.

© Henry J. Kaiser Family Foundation. All rights reserved.



Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Drug Makers Hike Prices, Lobby Hard As Reform Efforts Progress." Medical News Today. MediLexicon, Intl., 17 Nov. 2009. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/171153.php>

APA
Kaiser. (2009, November 17). "Drug Makers Hike Prices, Lobby Hard As Reform Efforts Progress." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/171153.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »